

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)



(10) International Publication Number
WO 2022/068848 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) A61K 31/4965 (2006.01)
C07D 241/20 (2006.01) A61K 31/4152 (2006.01)
C07D 231/20 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2021/121562

(22) International Filing Date:

29 September 2021 (29.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/119171
30 September 2020 (30.09.2020) CN
PCT/CN2020/135968
11 December 2020 (11.12.2020) CN
PCT/CN2021/076993
20 February 2021 (20.02.2021) CN
PCT/CN2021/113967
23 August 2021 (23.08.2021) CN

(71) Applicant: **BEIGENE, LTD.** [GB/GB]; c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108 Cayman Islands (KY).

(72) Inventor; and

(71) Applicant (for SC only): **XU, Sanjia** [CN/CN]; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN).

(72) Inventors: **LI, Jing**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). **WANG, Zhiwei**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3 FL, Building 2, Yard 3, Fengxiuzhonglu Road, Haidian District, Beijing 100094 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF



(57) Abstract: Disclosed herein is 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g., inhibiting or treating HPK1 related disorders or diseases including cancer by using the compound disclosed herein

WO 2022/068848 A1